Literature DB >> 8239560

Correlation between magnetic resonance imaging findings and lesion development in chronic, active multiple sclerosis.

D Katz1, J K Taubenberger, B Cannella, D E McFarlin, C S Raine, H F McFarland.   

Abstract

Magnetic resonance imaging is a highly sensitive method for the detection of the lesions of multiple sclerosis and renders possible the study and the evolution of early lesions. Previous reports on magnetic resonance imaging following gadolinium-diethylenetriamine pentaacetic acid (Gd-DTPA) injection demonstrated that new lesions can be recognized by contrast enhancement. The pathological basis of these observations is uncertain. We have had the opportunity to study at autopsy the brain of a patient with chronic progressive multiple sclerosis who suffered acute worsening leading to death. Magnetic resonance imaging performed 10 days and 4 weeks prior to death showed new Gd-DTPA-enhanced lesions in the posterior hemispheric white matter adjacent to the lateral ventricles. Light microscopic examination of these areas demonstrated them to be fresh lesions comprising intense inflammatory activity and dense perivascular cuffs within an edematous lesion center and a striking parenchymal mononuclear cell infiltration at the margins of the lesions. Lesions that were demonstrated by increased signal on T2-weighted images, but were not enhanced following administration of Gd-DTPA, were all of the chronic type, either inactive or active. None of these showed the intense inflammatory activity of the acute lesions and most displayed fibrous astrogliosis.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8239560     DOI: 10.1002/ana.410340507

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  59 in total

Review 1.  Physicians, subsequence and consequence.

Authors:  W I McDonald
Journal:  J Neurol Neurosurg Psychiatry       Date:  1999-09       Impact factor: 10.154

Review 2.  Neuroimaging techniques in the diagnostic work-up of patients with the antiphospholipid syndrome.

Authors:  M Rovaris; C Pedroso; M Filippi
Journal:  Curr Rheumatol Rep       Date:  2001-08       Impact factor: 4.592

3.  Whole-brain atrophy in multiple sclerosis measured by automated versus semiautomated MR imaging segmentation.

Authors:  Jitendra Sharma; Michael P Sanfilipo; Ralph H B Benedict; Bianca Weinstock-Guttman; Frederick E Munschauer; Rohit Bakshi
Journal:  AJNR Am J Neuroradiol       Date:  2004 Jun-Jul       Impact factor: 3.825

Review 4.  Targeting the neurovascular unit for treatment of neurological disorders.

Authors:  Reyna L Vangilder; Charles L Rosen; Taura L Barr; Jason D Huber
Journal:  Pharmacol Ther       Date:  2010-12-21       Impact factor: 12.310

5.  Magnetisation transfer ratios of contrast-enhancing and nonenhancing lesions in multiple sclerosis.

Authors:  A Campi; M Filippi; G Comi; G Scotti; S Gerevini; V Dousset
Journal:  Neuroradiology       Date:  1996-02       Impact factor: 2.804

6.  Differentiation and quantification of inflammation, demyelination and axon injury or loss in multiple sclerosis.

Authors:  Yong Wang; Peng Sun; Qing Wang; Kathryn Trinkaus; Robert E Schmidt; Robert T Naismith; Anne H Cross; Sheng-Kwei Song
Journal:  Brain       Date:  2015-02-26       Impact factor: 13.501

7.  In vivo quantitative evaluation of brain tissue damage in multiple sclerosis using gradient echo plural contrast imaging technique.

Authors:  Pascal Sati; Anne H Cross; Jie Luo; Charles F Hildebolt; Dmitriy A Yablonskiy
Journal:  Neuroimage       Date:  2010-03-23       Impact factor: 6.556

Review 8.  Imaging of multiple sclerosis: role in neurotherapeutics.

Authors:  Rohit Bakshi; Alireza Minagar; Zeenat Jaisani; Jerry S Wolinsky
Journal:  NeuroRx       Date:  2005-04

9.  Characterizing contrast-enhancing and re-enhancing lesions in multiple sclerosis.

Authors:  Z Campbell; D Sahm; K Donohue; J Jamison; M Davis; C Pellicano; S Auh; J Ohayon; J A Frank; N Richert; F Bagnato
Journal:  Neurology       Date:  2012-04-25       Impact factor: 9.910

10.  Insulin-like growth factor I treatment reduces demyelination and up-regulates gene expression of myelin-related proteins in experimental autoimmune encephalomyelitis.

Authors:  D L Yao; X Liu; L D Hudson; H D Webster
Journal:  Proc Natl Acad Sci U S A       Date:  1995-06-20       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.